TrialThe Lancet. Haematology2023

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.

Paul G Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.